NCT04702321Recruiting
Genetic Risks for Childhood Cancer Complications in Switzerland
Source: ClinicalTrials.gov · Last updated 13 Jan 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The objectives of the GECCOS project are to identify genetic variants associated with complications of childhood cancer using genotype-phenotype association studies. Germline genetic samples and data of the "Germline DNA Biobank for Childhood Cancer and Blood Disorders Switzerland" (BISKIDS) which is included in the Geneva Biobank for Hematology and Oncology in Pediatrics (BaHOP) will be used with clinical data of Swiss childhood cancer patients collected at the Institute of Social and Preventive Medicine in Bern.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 6000 (estimated)
- First submitted
- 21 Dec 2020
- Start date
- 1 Dec 2020
- Primary completion date
- 31 Dec 2037
- Lead sponsor
- University Hospital, Geneva
- Diseases
- Childhood cancers
- NCT number
- NCT04702321
What you commit to
- Study type: Observational
- Planned participants: 6000
- From 1 Dec 2020 to the primary completion date, 31 Dec 2037
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Lacking written consent signed by participant and/ or their legal representative to participate in the BaHOP (where applicable); OR
- died after study participation and declined use of their samples and data after their death in the original consent for BaHOP (as indicated on the BaHOP consent).
Who the study is looking for
- Registered in the Swiss Childhood Cancer Registry (SCCR) since 1976; AND
- consented to the BaHOP (host biobank for the BISKIDS Biobanking project); AND
- diagnosed with cancer according to the International Classification of Childhood Cancer, version 3, ICCC-3, or Langerhans cell histiocytosis (LCH) before age 21 years.
Age in the registry: - to 21 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Geneva Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.